RNA-Seq analysis of prostate tumors with or without androgen receptor splice variant
Transcriptomics Dataset
FAIR Metrics
0 evaluations
General Information
| Accession | GSE56701 |
| Title | RNA-Seq analysis of prostate tumors with or without androgen receptor splice variant |
| Description | Background. Androgen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor protein which lacks the ligand-binding domain, the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of AR-V7 in circulating tumor cells (CTCs) from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone. Methods. We used quantitative reverse-transcription polymerase-chain-reaction (qRT-PCR) to interrogate CTCs for the presence or absence of AR-V7 from prospectively enrolled patients with metastatic castration-resistant prostate cancer initiating treatment with either enzalutamide or abiraterone. We examined associations between AR-V7 status and PSA response rates, PSA-progression-free-survival (PSA-PFS), clinical/radiographic-progression-free-survival (PFS), and overall survival (OS). Multivariable Cox regression analyses were performed to determine the independent effect of AR-V7 status on clinical outcomes. Results. Thirty-one enzalutamide-treated patients and thirty-one abiraterone-treated patients were enrolled, of which 38.7%% and 19.4%% had detectable AR-V7 from CTCs, respectively. Among men receiving enzalutamide, AR-V7positive patients had inferior PSA response rates (0%% vs 52.6%%, P=0.004), PSA-PFS (median: 1.4 vs 6.0 months, P<0.001), PFS (median: 2.1 vs 6.1 months, P<0.001), and OS (median: 5.5 months vs not reached, P=0.002) compared to AR-V7negative patients. Similarly, among men receiving abiraterone, AR-V7positive patients had inferior PSA response rates (0%% vs 68.0%%, P=0.004), PSA-PFS (median: 1.3 months vs not reached, P<0.001), PFS (median: 2.3 months vs not reached, P<0.001), and OS (median: 10.6 months vs not reached, P=0.006). The negative prognostic impact of AR-V7 was maintained after adjusting for full-length-AR expression. Conclusions. Detection of AR-V7 in CTCs from patients with castration-resistant prostate cancer is associated with resistance to enzalutamide and abiraterone. |
| Landing Page | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56701 |
| Repository | Gene Expression Omnibus |
Related Datasets
GSE69896
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
1
GSE71334
mRNA differential expression in LNCaP cells expressing the wild-type androgen receptor (AR-WT) or the ligand-independent AR-V7 splice variant
1
GSE61281
Human Whole Blood: Psoriatic Arthritis [PsA] vs. Cutaneous Psoriasis Without Arthritis [PsC] vs. Controls
14
GSE49244
Abiraterone acetate and di-n-butyl phthalate (DBP) response in a human fetal testis xenograft bioassay
7
Tools
used to analyze the dataset
Canned Analyses
generated with the dataset
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.
